Immunovant, Inc.

Immunovant, Inc.

Biotechnology • Healthcare • New York, NY, United States • IMVT (NMS)

Immunovant, Inc., a clinical-stage immunology company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1402 for graves' disease, rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, cutaneous lupus erythematosus disease, and sjögren's disease; and batoclimab for myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and thyroid eye disease. The company was founded in 2018 and is based in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.

917 580 3099 320 West 37th Street, New York, NY 10018, United States

Stock Performance (90 Days)

Data through Dec 29, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Roivant Sciences buys Immunovant (IMVT) shares worth $349.9m - Investing.com
Investing.com • Dec 12
Immunovant, Inc. (NASDAQ:IMVT) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
MarketBeat • Dec 29
Is Immunovant (IMVT) Overvalued? Taking Stock of Its Premium Price-to-Book Multiple - Yahoo Finance
Yahoo Finance • Dec 2
Why Immunovant Stock Blasted Higher Today - The Motley Fool
The Motley Fool • Sep 3
Immunovant: "Buy" On Competitive Batoclimab Landscape And IMVT-1402 Advancement (IMVT) - Seeking Alpha
Seeking Alpha • Dec 12

Other Biotechnology Companies

View All →
CODEXIS, INC. logo Codexis, Inc.
1 layoff tracked
$144.5M market cap
VERTEX PHARMACEUTICALS INC / MA logo Vertex Pharmaceuticals Inc. / MA
$118.68B market cap
REGENERON PHARMACEUTICALS, INC. logo Regeneron Pharmaceuticals, Inc.
$82.72B market cap
ALNYLAM PHARMACEUTICALS, INC. logo Alnylam Pharmaceuticals, Inc.
$52.92B market cap
ARGENX SE logo Argenx SE
$52.62B market cap
INSMED Inc logo Insmed Inc.
$37.61B market cap

Frequently Asked Questions

Has Immunovant, Inc. had layoffs?
No layoff events have been recorded for Immunovant, Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does Immunovant, Inc. have?
Immunovant, Inc. has approximately 362 employees.
What industry is Immunovant, Inc. in?
Immunovant, Inc. operates in the Biotechnology industry, within the Healthcare sector.
Is Immunovant, Inc. a publicly traded company?
Yes, Immunovant, Inc. is publicly traded under the ticker symbol IMVT on the NMS. The company has a market capitalization of approximately $5.16 billion.
Where is Immunovant, Inc. headquartered?
Immunovant, Inc. is headquartered in New York, NY, United States at 320 West 37th Street, New York, NY 10018, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.